Table 1.
Cytokinin contents (in pmol g−1 FW) in four developmental stages (T1-T4) during kohlrabi (cv. Vienna Purple) growth and de novo shoot organogenesis on media containing different cytokinins and increasing concentration of sucrose. Endogenous cytokinins are divided into 4 groups based on their side chain structure: cisZ-, transZ-, DHZ- and iP-types.
| Cytokinin treatment | Sugar conc. (%) | CK content (pmol g−1 FW) | |||
|---|---|---|---|---|---|
| cisZ type | transZ type | DHZ type | iP type | ||
| T1 | |||||
| No CK | 3 | 96.84 ± 74.28 a | 9.09 ± 1.45 b | 2.55 ± 0.50 a | 15.34 ± 0.97 c |
| 6 | 71.45 ± 48.88 a | 14.28 ± 2.78 ab | 2.44 ± 0.25 a | 38.40 ± 0.37b | |
| 9 | 63.85 ± 36.65 a | 17.64 ± 1.95 a | 4.09 ± 0.94 a | 51.60 ± 2.32 a | |
| transZ | 3 | 41.80 ± 8.75 b | 2247.70 ± 231.64 b | 166.43 ± 21.16 b | 29.35 ± 2.51 b |
| 6 | 64.06 ± 19.72 ab | 2376.38 ± 131.90 b | 319.70 ± 39.30 b | 29.08 ± 1.67 b | |
| 9 | 228.30 ± 87.05 a | 35,140.84 ± 3468.62 a | 3278.25 ± 197.90 a | 78.60 ± 5.71 a | |
| TDZ | 3 | 60.93 ± 40.68 a | 7.67 ± 0.73 b | 4.11 ± 0.39 a | 19.70 ± 1.05 b |
| 6 | 68.17 ± 43.23 a | 8.27 ± 0.21 b | 6.52 ± 2.84 a | 16.65 ± 1.08 b | |
| 9 | 94.18 ± 57.81 a | 45.60 ± 4.91a | 3.75 ± 0.78 a | 41.77 ± 2.77 a | |
| T2 | |||||
| No CK | 3 | 67.03 ± 30.97 a | 638.21 ± 41.52 a | 84.22 ± 16.14 a | 26.79 ± 2.46 c |
| 6 | 125.25 ± 50.63 a | 20.93 ± 1.06 b | 1.80 ± 0.47 b | 37.33 ± 0.52 b | |
| 9 | 89.60 ± 44.95 a | 26.89 ± 0.84 b | 7.29 ± 2.35 b | 57.24 ± 2.77 a | |
| transZ | 3 | 102.78 ± 34.22 ab | 2311.24 ± 22.96 b | 98.53 ± 12.76 b | 31.94 ± 1.53 b |
| 6 | 35.64 ± 4.99 b | 2384.89 ± 128.18 b | 274.48 ± 38.82 b | 16.99 ± 1.42 c | |
| 9 | 269.89 ± 85.43 a | 21,013.27 ± 1028.41 a | 1798.27 ± 218.80 a | 52.87 ± 3.59 a | |
| TDZ | 3 | 58.91 ± 40.57 a | 7.01 ± 2.11 c | 2.41 ± 0.72 a | 20.68 ± 4.94 a |
| 6 | 56.07 ± 24.62 a | 15.21 ± 0.40 b | 5.85 ± 2.04 a | 17.44 ± 0.63 a | |
| 9 | 73.24 ± 13.59 a | 25.00 ± 2.45 a | 1.96 ± 0.40 a | 23.99 ± 1.97 a | |
| T3 | |||||
| No CK | 3 | 69.15 ± 45.01 a | 15.42 ± 1.57 b | 2.36 ± 0.30 b | 29.96 ± 1.47 c |
| 6 | 59.84 ± 32.13 a | 16.37 ± 0.53 b | 1.41 ± 0.24 c | 38.82 ± 2.53 b | |
| 9 | 61.02 ± 22.96 a | 22.55 ± 1.25 a | 3.21 ± 0.13 a | 52.01 ± 2.50 a | |
| transZ | 3 | 80.94 ± 57.41 b | 772.96 ± 60.19 b | 197.06 ± 29.13 b | 14.54 ± 0.61 b |
| 6 | 49.36 ± 21.34 b | 1023.35 ± 46.65 b | 406.24 ± 58.43 b | 26.73 ± 2.53 b | |
| 9 | 386.34 ± 20.75 a | 39,099.20 ± 2418.814 a | 6952.81 ± 1174.29 a | 84.04 ± 21.29 a | |
| TDZ | 3 | 60.99 ± 36.34 a | 32.07 ± 7.22 a | 1.60 ± 0.38 a | 36.90 ± 2.23 b |
| 6 | 41.02 ± 16.98 a | 8.40 ± 0.36 b | 4.46 ± 1.59 a | 16.15 ± 1.82 b | |
| 9 | 43.22 ± 12.01 a | 13.53 ± 4.13 b | 1.75 ± 0.86 a | 21.78 ± 1.13 a | |
| T4 | |||||
| No CK | 3 | 46.85 ± 27.61a | 39.50 ± 2.68 a | 2.13 ± 0.22 a | 36.01 ± 1.22 c |
| 6 | 74.31 ± 49.59 a | 23.21 ± 0.25 b | 1.93 ± 0.31 a | 56.27 ± 4.78 b | |
| 9 | 126.09 ± 85.78 a | 25.93 ± 2.22 b | 2.63 ± 0.29 a | 77.06 ± 3.26 a | |
| transZ | 3 | 84.33 ± 33.71 a | 259.19 ± 9.91 b | 72.15 ± 16.26 b | 26.53 ± 1.13 b |
| 6 | 73.82 ± 41.74 a | 264.72 ± 6.43 b | 7.60 ± 0.17 b | 21.19 ± 0.40 b | |
| 9 | 328.59 ± 153.74 a | 13,799.69 ± 371.035 a | 23,042.35 ± 226.27 a | 46.98 ± 3.37 a | |
| TDZ | 3 | 52.66 ± 26.16 a | 6.01 ± 1.52 b | 1.07 ± 0.22 b | 16.18 ± 1.47 a |
| 6 | 45.12 ± 17.37 a | 10.30 ± 1.41 ab | 14.06 ± 5.90 a | 16.75 ± 1.09 a | |
| 9 | 48.40 ± 7.71 a | 16.94 ± 3.12 a | 1.73 ± 0.27 b | 16.36 ± 0.40 a | |
Results are presented as mean ± SE (n = 3). Different letters indicate statistically significant difference between means within a column for each developmental stage and for each CK treatment according to Fisher’s Least Significant Difference (LSD) test, P ≤ 0.05.
(transZ = trans-zeatin 2 mg L−1, TDZ = thidiazuron 2 mg L−1).